<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">35808822</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2001-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Clinical and translational medicine</Title><ISOAbbreviation>Clin Transl Med</ISOAbbreviation></Journal><ArticleTitle>Identification of growth hormone receptor as a relevant target for precision medicine in low-EGFR expressing glioblastoma.</ArticleTitle><Pagination><MedlinePgn>e939</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ctm2.939</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">New therapeutic approaches are needed to improve the prognosis of glioblastoma (GBM) patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">With the objective of identifying alternative oncogenic mechanisms to abnormally activated epidermal growth factor receptor (EGFR) signalling, one of the most common oncogenic mechanisms in GBM, we performed a comparative analysis of gene expression profiles in a series of 54 human GBM samples. We then conducted gain of function as well as genetic and pharmocological inhibition assays in GBM patient-derived cell lines to functionnally validate our finding.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified that growth hormone receptor (GHR) signalling defines a distinct molecular subset of GBMs devoid of EGFR overexpression. GHR overexpression was detected in one third of patients and was associated with low levels of suppressor of cytokine signalling 2 (SOCS2) expression due to SOCS2 promoter hypermethylation. In GBM patient-derived cell lines, GHR signalling modulates the expression of proteins involved in cellular movement, promotes cell migration, invasion and proliferation in vitro and promotes tumourigenesis, tumour growth, and tumour invasion in vivo. GHR genetic and pharmacological inhibition reduced cell proliferation and migration in vitro.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study pioneers a new field of investigation to improve the prognosis of GBM patients.</AbstractText><CopyrightInformation>© 2022 The Authors. Clinical and Translational Medicine published by John Wiley &amp; Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Verreault</LastName><ForeName>Maïté</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-6708-7698</Identifier><AffiliationInfo><Affiliation>Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Segoviano Vilchis</LastName><ForeName>Irma</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Shai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory for Cancer Computational Biology &amp; Gaffin Center for Neuro-Oncology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemaire</LastName><ForeName>Nolwenn</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmitt</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guehennec</LastName><ForeName>Jérémy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Royer-Perron</LastName><ForeName>Louis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>DMU Neurosciences, Service de Neurologie 2-Mazarin, Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Jean-Léon</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>TuKiet T</ForeName><Initials>TT</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-4850-3462</Identifier><AffiliationInfo><Affiliation>Mass Spectrometry &amp; Proteomics Resource, Keck Biotechnology Resource Laboratory, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dingli</LastName><ForeName>Florent</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institut Curie, Centre de Recherche, PSL Research University, Laboratoire de Spectrométrie de Masse Protéomique, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loew</LastName><ForeName>Damarys</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institut Curie, Centre de Recherche, PSL Research University, Laboratoire de Spectrométrie de Masse Protéomique, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ducray</LastName><ForeName>François</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hôpital Neurologique, Service de Neurologie B, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paris</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carpentier</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marie</LastName><ForeName>Yannick</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laigle-Donadey</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>DMU Neurosciences, Service de Neurologie 2-Mazarin, Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rousseau</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DMU Neurosciences, Service de Neurologie 2-Mazarin, Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pigat</LastName><ForeName>Natascha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Université Paris Cité, INSERM UMR-S1151, CNRS UMR-S8253, Institut Necker Enfants Malades, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boutillon</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Université Paris Cité, INSERM UMR-S1151, CNRS UMR-S8253, Institut Necker Enfants Malades, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bielle</LastName><ForeName>Franck</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>DMU Neurosciences, Service de Neurologie 2-Mazarin, Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mokhtari</LastName><ForeName>Karima</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>DMU Neurosciences, Service de Neurologie 2-Mazarin, Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frank</LastName><ForeName>Stuart J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Alabama, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Endocrinology Section, Medical Service, Birmingham VA Medical Center, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Reyniès</LastName><ForeName>Aurélien</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, Service de Bioinformatique, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoang-Xuan</LastName><ForeName>Khê</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>DMU Neurosciences, Service de Neurologie 2-Mazarin, Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanson</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>DMU Neurosciences, Service de Neurologie 2-Mazarin, Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goffin</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Université Paris Cité, INSERM UMR-S1151, CNRS UMR-S8253, Institut Necker Enfants Malades, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Idbaih</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>DMU Neurosciences, Service de Neurologie 2-Mazarin, Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Transl Med</MedlineTA><NlmUniqueID>101597971</NlmUniqueID><ISSNLinking>2001-1326</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cell migration</Keyword><Keyword MajorTopicYN="N">comparative analysis</Keyword><Keyword MajorTopicYN="N">glioblastoma</Keyword><Keyword MajorTopicYN="N">oncogenicity</Keyword><Keyword MajorTopicYN="N">pre-clinical models</Keyword><Keyword MajorTopicYN="N">therapeutic target</Keyword><Keyword MajorTopicYN="N">tumour invasion</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>05</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>01</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>06</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>9</Day><Hour>1</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35808822</ArticleId><ArticleId IdType="doi">10.1002/ctm2.939</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977-2000. Cancer. 2004;101:2293-2299.</Citation></Reference><Reference><Citation>Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109.</Citation></Reference><Reference><Citation>Bauchet L, Rigau V, Mathieu-Daude H, et al. French brain tumor data bank: methodology and first results on 10,000 cases. J Neurooncol. 2007;84:189-199.</Citation></Reference><Reference><Citation>Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.</Citation></Reference><Reference><Citation>Keime-Guibert F, Chinot O, Taillandier L, et al.; Association of French-Speaking Neuro-Oncologists. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356:1527-1535.</Citation></Reference><Reference><Citation>Vredenburgh JJ, Desjardins A. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722-4729.</Citation></Reference><Reference><Citation>Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21:2683-2710.</Citation></Reference><Reference><Citation>Collins VP. Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry. 2004;75(suppl 2):ii2-11.</Citation></Reference><Reference><Citation>Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061-1068.</Citation></Reference><Reference><Citation>Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807-1812.</Citation></Reference><Reference><Citation>Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64:6892-6899.</Citation></Reference><Reference><Citation>Verhaak RG, Hoadley KA, Purdom E, et al.; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98-110.</Citation></Reference><Reference><Citation>Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462-477.</Citation></Reference><Reference><Citation>Lau D, Magill ST, Aghi MK. Molecularly targeted therapies for recurrent glioblastoma: current and future targets. Neurosurg Focus. 2014;37:E15.</Citation></Reference><Reference><Citation>Mellinghoff IK, Schultz N, Mischel PS, Cloughesy TF. Will kinase inhibitors make it as glioblastoma drugs?. Curr Top Microbiol Immunol. 2012;355:135-169.</Citation></Reference><Reference><Citation>Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003;63:6962-6970.</Citation></Reference><Reference><Citation>Vollmann-Zwerenz A, Leidgens V, Feliciello G, Klein CA, Hau P. Tumor cell invasion in glioblastoma. Int J Mol Sci. 2020;21:1932.</Citation></Reference><Reference><Citation>Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9:157-173.</Citation></Reference><Reference><Citation>Freije WA, Castro-Vargas FE, Fang Z, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004;64:6503-6510.</Citation></Reference><Reference><Citation>Sun L, Hui AM, Su Q, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell. 2006;9:287-300.</Citation></Reference><Reference><Citation>Chhabra Y, Lee CMM, Muller AF, Brooks AJ. GHR signalling: receptor activation and degradation mechanisms. Mol Cell Endocrinol. 2021;520:111075.</Citation></Reference><Reference><Citation>Strous GJ, Almeida ADS, Putters J, et al. Growth hormone receptor regulation in cancer and chronic diseases. Front Endocrinol (Lausanne). 2020;11:597573.</Citation></Reference><Reference><Citation>Davey HW, McLachlan MJ, Wilkins RJ, Hilton DJ, Adams TE. STAT5b mediates the GH-induced expression of SOCS-2 and SOCS-3 mRNA in the liver. Mol Cell Endocrinol. 1999;158:111-116.</Citation></Reference><Reference><Citation>Greenhalgh CJ, Bertolino P, Asa SL, et al. Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b). Mol Endocrinol. 2002;16:1394-1406.</Citation></Reference><Reference><Citation>Leroith D, Nissley P. Knock your SOCS off. J Clin Invest. 2005;115:233-236.</Citation></Reference><Reference><Citation>Flores-Morales A, Greenhalgh CJ, Norstedt G, Rico-Bautista E. Negative regulation of growth hormone receptor signaling. Mol Endocrinol. 2006;20:241-253.</Citation></Reference><Reference><Citation>Vesterlund M, Zadjali F, Persson T, et al. The SOCS2 ubiquitin ligase complex regulates growth hormone receptor levels. PLoS One. 2011;6:e25358.</Citation></Reference><Reference><Citation>He K, Loesch K, Cowan JW, et al. Janus kinase 2 enhances the stability of the mature growth hormone receptor. Endocrinology. 2005;146:4755-4765.</Citation></Reference><Reference><Citation>Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401-404.</Citation></Reference><Reference><Citation>Noushmehr H, Weisenberger DJ, Diefes K, et al.; Cancer Genome Atlas Research Network. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17:510-522.</Citation></Reference><Reference><Citation>Latta F, Leproult R, Tasali E, et al. Sex differences in nocturnal growth hormone and prolactin secretion in healthy older adults: relationships with sleep EEG variables. Sleep. 2005;28:1519-1524.</Citation></Reference><Reference><Citation>Letellier E, Schmitz M, Baig K, et al. Identification of SOCS2 and SOCS6 as biomarkers in human colorectal cancer. Br J Cancer. 2014;111:726-735.</Citation></Reference><Reference><Citation>Behncken SN, Billestrup N, Brown R, Amstrup J, Conway-Campbell B, Waters MJ. Growth hormone (GH)-independent dimerization of GH receptor by a leucine zipper results in constitutive activation. J Biol Chem. 2000;275:17000-17007.</Citation></Reference><Reference><Citation>Rowlinson SW, Yoshizato H, Barclay JL, et al. An agonist-induced conformational change in the growth hormone receptor determines the choice of signalling pathway. Nat Cell Biol. 2008;10:740-747.</Citation></Reference><Reference><Citation>Vizcaino JA, Csordas A, del-Toro N, et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 2016;44:D447-56.</Citation></Reference><Reference><Citation>Ji S, Frank SJ, Messina JL. Growth hormone-induced differential desensitization of STAT5, ERK, and Akt phosphorylation. J Biol Chem. 2002;277:28384-28393.</Citation></Reference><Reference><Citation>Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996;12:697-715.</Citation></Reference><Reference><Citation>Oharazawa H, Ibaraki N, Ohara K, Reddy VN. Inhibitory effects of Arg-Gly-Asp (RGD) peptide on cell attachment and migration in a human lens epithelial cell line. Ophthalmic Res. 2005;37:191-196.</Citation></Reference><Reference><Citation>Dehkhoda F, Lee CMM, Medina J, Brooks AJ. The growth hormone receptor: mechanism of receptor activation, cell signaling, and physiological aspects. Front Endocrinol. 2018;9:35.</Citation></Reference><Reference><Citation>An Z, Aksoy O, Zheng T, Fan QW, Weiss WA. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene. 2018;37:1561-1575.</Citation></Reference><Reference><Citation>Kim Y, Varn FS, Park SH, et al. Perspective of mesenchymal transformation in glioblastoma. Acta Neuropathol Commun. 2021;9:50.</Citation></Reference><Reference><Citation>Stewart RL, O'Connor KL. Clinical significance of the integrin alpha6beta4 in human malignancies. Lab Invest. 2015;95:976-986.</Citation></Reference><Reference><Citation>Koistinen P, Heino J. Integrins in cancer cell invasion. Madame Curie Bioscience Database. Landes Bioscience; 2000.</Citation></Reference><Reference><Citation>Mukhina S, Mertani HC, Guo K, Lee KO, Gluckman PD, Lobie PE. Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. Proc Nat Acad Sci USA. 2004;101:15166-15171.</Citation></Reference><Reference><Citation>Perry JK, Liu DX, Wu ZS, Zhu T, Lobie PE. Growth hormone and cancer: an update on progress. Curr Opin Endocrinol Diabetes Obes. 2013;20:307-313.</Citation></Reference><Reference><Citation>Chang L, Qi H, Xiao Y, et al. Integrated analysis of noncoding RNAs and mRNAs reveals their potential roles in the biological activities of the growth hormone receptor. Growth Horm IGF Res. 2016;29:11-20.</Citation></Reference><Reference><Citation>Castro JR, Costoya JA, Gallego R, Prieto A, Arce VM, Senaris R. Expression of growth hormone receptor in the human brain. Neurosci Lett. 2000;281:147-150.</Citation></Reference><Reference><Citation>Lea RW, Dawson T, Martinez-Moreno CG, El-Abry N, Harvey S. Growth hormone and cancer: gH production and action in glioma?. Gen Comp Endocrinol. 2015;220:119-123.</Citation></Reference><Reference><Citation>Wu ZS, Yang K, Wan Y, et al. Tumor expression of human growth hormone and human prolactin predict a worse survival outcome in patients with mammary or endometrial carcinoma. J Clin Endocrinol Metab. 2011;96:E1619-E1629.</Citation></Reference><Reference><Citation>Lincoln DT, Sinowatz F, Kolle S, Takahashi H, Parsons P, Waters M. Up-regulation of growth hormone receptor immunoreactivity in human melanoma. Anticancer Res. 1999;19:1919-1931.</Citation></Reference><Reference><Citation>Gebre-Medhin M, Kindblom LG, Wennbo H, Tornell J, Meis-Kindblom JM. Growth hormone receptor is expressed in human breast cancer. Am J Pathol. 2001;158:1217-1222.</Citation></Reference><Reference><Citation>Weiss-Messer E, Merom O, Adi A, et al. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells. Mol Cell Endocrinol. 2004;220:109-123.</Citation></Reference><Reference><Citation>Perry JK, Emerald BS, Mertani HC, Lobie PE. The oncogenic potential of growth hormone. Growth Horm IGF Res. 2006;16:277-289.</Citation></Reference><Reference><Citation>Pereira B, Chin SF, Rueda OM, et al. Erratum: the somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11908.</Citation></Reference><Reference><Citation>Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479.</Citation></Reference><Reference><Citation>Wu X, Wan M, Li G, et al. Growth hormone receptor overexpression predicts response of rectal cancers to pre-operative radiotherapy. Eur J Cancer. 2006;42:888-894.</Citation></Reference><Reference><Citation>Elzein S, Goodyer CG. Regulation of human growth hormone receptor expression by microRNAs. Mol Endocrinol. 2014;28:1448-1459.</Citation></Reference><Reference><Citation>Martini M, Pallini R, Luongo G, Cenci T, Lucantoni C, Larocca LM. Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. Int J Cancer. 2008;123:2955-2960.</Citation></Reference><Reference><Citation>Ashpole NM, Sanders JE, Hodges EL, Yan H, Sonntag WE. Growth hormone, insulin-like growth factor-1 and the aging brain. Exp Gerontol. 2015;68:76-81.</Citation></Reference><Reference><Citation>Pan W, Yu Y, Cain CM, Nyberg F, Couraud PO, Kastin AJ. Permeation of growth hormone across the blood-brain barrier. Endocrinology. 2005;146:4898-4904.</Citation></Reference><Reference><Citation>van den Eijnden MJ, Strous GJ. Autocrine growth hormone: effects on growth hormone receptor trafficking and signaling. Mol Endocrinol. 2007;21:2832-2846.</Citation></Reference><Reference><Citation>McCutcheon IE, Flyvbjerg A, Hill H, et al. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg. 2001;94:487-492.</Citation></Reference><Reference><Citation>Dagnaes-Hansen F, Duan H, Rasmussen LM, Friend KE, Flyvbjerg A. Growth hormone receptor antagonist administration inhibits growth of human colorectal carcinoma in nude mice. Anticancer Res. 2004;24:3735-3742.</Citation></Reference><Reference><Citation>Divisova J, Kuiatse I, Lazard Z, et al. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat. 2006;98:315-327.</Citation></Reference><Reference><Citation>Evans A, Jamieson SM, Liu DX, Wilson WR, Perry JK. Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model. Cancer Lett. 2016;379:117-123.</Citation></Reference><Reference><Citation>Basu R, Wu S, Kopchick JJ. Targeting growth hormone receptor in human melanoma cells attenuates tumor progression and epithelial mesenchymal transition via suppression of multiple oncogenic pathways. Oncotarget. 2017;8:21579-21598.</Citation></Reference><Reference><Citation>Zhou D, Zhang YI, Liang D, et al. Effect of combination therapy of siRNA targeting growth hormone receptor and 5-fluorouracil in hepatic metastasis of colon cancer. Oncol Lett. 2015;10:3505-3509.</Citation></Reference><Reference><Citation>Veldhuis JD, Bidlingmaier M, Bailey J, Erickson D, Sandroni P. A pegylated growth hormone receptor antagonist, pegvisomant, does not enter the brain in humans. J Clin Endocrinol Metab. 2010;95:3844-3847.</Citation></Reference><Reference><Citation>Lu M, Flanagan JU, Langley RJ, Hay MP, Perry JK. Targeting growth hormone function: strategies and therapeutic applications. Signal Transduct Target Ther. 2019;4:3.</Citation></Reference><Reference><Citation>Jaeger LB, Banks WA, Varga JL, Schally AV. Antagonists of growth hormone-releasing hormone cross the blood-brain barrier: a potential applicability to treatment of brain tumors. Proc Nat Acad Sci USA. 2005;102:12495-12500.</Citation></Reference><Reference><Citation>Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31:e15.</Citation></Reference><Reference><Citation>Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Nat Acad Sci USA. 2001;98:31-36.</Citation></Reference><Reference><Citation>Puchalski RB, Shah N, Miller J, et al. An anatomic transcriptional atlas of human glioblastoma. Science. 2018;360:660-663.</Citation></Reference><Reference><Citation>Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougneres P. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet. 2004;36:720-724.</Citation></Reference><Reference><Citation>Campeau E, Ruhl VE, Rodier F, et al. A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One. 2009;4:e6529.</Citation></Reference><Reference><Citation>Plessier A, Le Dret L, Varlet P, et al. New in vivo avatars of diffuse intrinsic pontine gliomas (DIPG) from stereotactic biopsies performed at diagnosis. Oncotarget. 2017;8:52543-52559.</Citation></Reference><Reference><Citation>Zennou V, Serguera C, Sarkis C, et al. The HIV-1 DNA flap stimulates HIV vector-mediated cell transduction in the brain. Nat Biotechnol. 2001;19:446-450.</Citation></Reference><Reference><Citation>Delenda C, Gaillard C. Real-time quantitative PCR for the design of lentiviral vector analytical assays. Gene Ther. 2005;12(1):S36-S50. Suppl.</Citation></Reference><Reference><Citation>Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA. Rational design of potent antagonists to the human growth hormone receptor. Science. 1992;256:1677-1680.</Citation></Reference><Reference><Citation>Chen WY, Chen NY, Yun J, Wagner TE, Kopchick JJ. In vitro and in vivo studies of antagonistic effects of human growth hormone analogs. J Biol Chem. 1994;269:15892-15897.</Citation></Reference><Reference><Citation>Paris N, Rentier-Delrue F, Defontaine A, et al. Bacterial production and purification of recombinant human prolactin. Biotechnol Appl Biochem. 1990;12:436-449.</Citation></Reference><Reference><Citation>Poullet P, Carpentier S, Barillot E. myProMS, a web server for management and validation of mass spectrometry-based proteomic data. Proteomics. 2007;7:2553-2556.</Citation></Reference><Reference><Citation>Ritchie ME, Phipson B, Wu D, et al. LIMMA powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.</Citation></Reference><Reference><Citation>IPA. 2016; Available from: www.qiagen.com/ingenuity</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">35805192</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>13</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>04</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>CaMKII Inhibition Attenuates Distinct Gain-of-Function Effects Produced by Mutant Nav1.6 Channels and Reduces Neuronal Excitability.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2108</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells11132108</ELocationID><Abstract><AbstractText>Aberrant Nav1.6 activity can induce hyperexcitability associated with epilepsy. Gain-of-function mutations in the <i>SCN8A</i> gene encoding Nav1.6 are linked to epilepsy development; however, the molecular mechanisms mediating these changes are remarkably heterogeneous and may involve post-translational regulation of Nav1.6. Because calcium/calmodulin-dependent protein kinase II (CaMKII) is a powerful modulator of Nav1.6 channels, we investigated whether CaMKII modulates disease-linked Nav1.6 mutants. Whole-cell voltage clamp recordings in ND7/23 cells show that CaMKII inhibition of the epilepsy-related mutation R850Q largely recapitulates the effects previously observed for WT Nav1.6. We also characterized a rare missense variant, R639C, located within a regulatory hotspot for CaMKII modulation of Nav1.6. Prediction software algorithms and electrophysiological recordings revealed gain-of-function effects for R639C mutant channel activity, including increased sodium currents and hyperpolarized activation compared to WT Nav1.6. Importantly, the R639C mutation ablates CaMKII phosphorylation at a key regulatory site, T642, and, in contrast to WT and R850Q channels, displays a distinct response to CaMKII inhibition. Computational simulations demonstrate that modeled neurons harboring the R639C or R850Q mutations are hyperexcitable, and simulating the effects of CaMKII inhibition on Nav1.6 activity in modeled neurons differentially reduced hyperexcitability. Acute CaMKII inhibition may represent a promising mechanism to attenuate gain-of-function effects produced by Nav1.6 mutations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zybura</LastName><ForeName>Agnes S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Program in Medical Neuroscience, Paul and Carole Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahoo</LastName><ForeName>Firoj K</ForeName><Initials>FK</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hudmon</LastName><ForeName>Andy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cummins</LastName><ForeName>Theodore R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Program in Medical Neuroscience, Paul and Carole Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biology Department, School of Science, Indiana University-Purdue University Indianapolis, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54NS108874</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS053422</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CaMKII</Keyword><Keyword MajorTopicYN="N">Nav1.6</Keyword><Keyword MajorTopicYN="N">electrophysiology</Keyword><Keyword MajorTopicYN="N">phosphorylation</Keyword><Keyword MajorTopicYN="N">post-translational modification (PTM)</Keyword><Keyword MajorTopicYN="N">sodium channel</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>06</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>06</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>9</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35805192</ArticleId><ArticleId IdType="pii">cells11132108</ArticleId><ArticleId IdType="doi">10.3390/cells11132108</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
